Aim: 

of the study was to investigate the influence of pioglitazone (PPARgamma ligand) on basal gastric acid secretion in omeprazole – treated rats.

Methods: 

The study was carried out on 50 white rats. They were divided into three groups: I (control) – were injected with 0,2 ml H2O (per os); II – were injected with omeprazole (OM) (14mg/ kg, i.p.); III – were injected OM and pioglitazone (30mg/kg, per os). All drugs were injected during 28 days. Functional state of parietal cells and gastric mucosal hypertrophy was evaluated by basal gastric acid output (BGAO). BGAO was determined after 24 hours after last injection. BGAO was investigated under urethane anaesthesia (1.1 g/kg, i.p.) by method of isolated stomach perfusion by Ghosh and Shild. Also in rats was measured blood plasma gastrin concentration by radioimmunoassay method.

Results: 

It was established that in 28 days of OM injection BGAO and gastrin plasma level increased by 283.7% and 189.3% in comparison to control accordingly. After 28 days of pioglitazone and OM treatment BGAO was diminished by 53.4% in comparison to rats after 28 days of OM injection. But pioglitazone did not influence on augmentation of gastrin plasma level evoked by OM.

Conclusion: 

1) hypergastrinaemia evoked by OM lead to the general hyperplasia and hyperplastic mucosa has an increased capacity to produce acid; 2) compensatory effect of pioglitazone on BGAO may indicate for retardation of mucosal hypertrophy process evoked by hypergastrinaemia. Therefore PPARgamma receptor is a novel target for the development of new and effective anticancer therapies.